Interferon alpha 2 maintenance therapy may enable high rates of treatment discontinuation in chronic myeloid leukemia

Leukemia

Volumn 29, Issue 6, 2015, Pages 1331-1335

  Burchert, A ^a   Saussele, S ^b   Eigendorff, E ^c   Muller M C ^b   Sohlbach, K ^a   Inselmann, S ^a   Schutz C ^a   Metzelder, S K ^a   Ziermann, J ^c   Kostrewa, P ^a   Hoffmann, J ^a   Hehlmann, R ^b   Neubauer, A ^a   Hochhaus, A ^c  

^a UNIVERSITY HOSPITAL MARBURG   (Germany)

^b UNIVERSITY OF HEIDELBERG   (Germany)

^c JENA UNIVERSITY HOSPITAL   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

IMATINIB; PEGINTERFERON ALPHA2A; RECOMBINANT ALPHA2 INTERFERON; ALPHA INTERFERON; ALPHA2A INTERFERON; ANTINEOPLASTIC AGENT; BENZAMIDE DERIVATIVE; PIPERAZINE DERIVATIVE; PYRIMIDINE DERIVATIVE; RECOMBINANT PROTEIN;

ADULT; AGED; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CANCER PATIENT; CHRONIC MYELOID LEUKEMIA; CLINICAL ARTICLE; CLINICAL ASSESSMENT; COHORT ANALYSIS; CONTROLLED STUDY; CYTOGENETICS; DRUG EFFICACY; DRUG TOLERABILITY; DRUG WITHDRAWAL; FEMALE; FOLLOW UP; HUMAN; LEUKEMIA REMISSION; LOW DRUG DOSE; MALE; MIDDLE AGED; MOLECULAR REMISSION; MONOTHERAPY; PRIORITY JOURNAL; RECURRENCE FREE SURVIVAL; REMISSION; TREATMENT DURATION; TREATMENT RESPONSE; YOUNG ADULT; CANCER STAGING; DRUG COMBINATION; LEUKEMIA, MYELOGENOUS, CHRONIC, BCR-ABL POSITIVE; MORTALITY; NEOPLASM RECURRENCE, LOCAL; PATHOLOGY; PROGNOSIS; SURVIVAL RATE;

ADULT; AGED; ANTINEOPLASTIC AGENTS; BENZAMIDES; COHORT STUDIES; DRUG THERAPY, COMBINATION; FEMALE; FOLLOW-UP STUDIES; HUMANS; INTERFERON-ALPHA; LEUKEMIA, MYELOGENOUS, CHRONIC, BCR-ABL POSITIVE; MALE; MIDDLE AGED; NEOPLASM RECURRENCE, LOCAL; NEOPLASM STAGING; PIPERAZINES; PROGNOSIS; PYRIMIDINES; RECOMBINANT PROTEINS; REMISSION INDUCTION; SURVIVAL RATE; YOUNG ADULT;

EID: 84930575207     PISSN: 08876924     EISSN: 14765551     Source Type: Journal    
DOI: 10.1038/leu.2015.45     Document Type: Article

References (35)

1. Hehlmann R, Müller MC, Lauseker M, Hanfstein B, Fabarius A, Schreiber A et al. Deep molecular response is reached by the majority of patients treated with imatinib, predicts survival, and is achieved more quickly by optimized high-dose imatinib: results from the randomized CML-study IV. J Clin Oncol 2013; 32: 415-423.
2. Branford S, Yeung DT, Ross DM, Prime JA, Field CR, Altamura HK et al. Early molecular response and female sex strongly predict stable undetectable BCR-ABL1, the criteria for imatinib discontinuation in patients with CML. Blood 2013; 121: 3818-3824.
3. Baccarani M, Deininger MW, Rosti G, Hochhaus A, Soverini S, Apperley JF et al. European LeukemiaNet recommendations for the management of chronic myeloid leukemia. Blood 2013; 122: 872-884.
4. Koskenvesa P, Kreutzman A, Rohon P, Pihlman M, Vakkila E, Räsänen A et al. Imatinib and pegylated IFN-2b discontinuation in first-line chronic myeloid leukemia patients following a major molecular response. Eur J Haematol 2014; 92: 413-420.
5. Talpaz M, Kantarjian HM, McCredie KB, Keating MJ, Trujillo J, Gutterman J. Clinical investigation of human alpha interferon in chronic myelogenous leukemia. Blood 1987; 69: 1280-1288.
6. Talpaz M, Kantarjian HM, McCredie K, Trujillo JM, Keating MJ, Gutterman JU. Hematologic remission and cytogenetic improvement induced by recombinant human interferon alpha A in chronic myelogenous leukemia. N Engl J Med 1986; 314: 1065-1069.
7. Hehlmann R, Heimpel H, Hasford J, Kolb H-J, Pralle H, Hossfeld DK et al. Randomized comparison of interferon-alpha with busulfan and hydroxyurea in chronic myelogenous leukemia. The German CML Study Group. Blood 1994; 84: 4064-4077.
8. Guilhot F, Chastang C, Michallet M, Guerci A, Harousseau JL, Maloisel F et al. Interferon alfa-2b combined with cytarabine versus interferon alone in chronic myelogenous leukemia. French Chronic Myeloid Leukemia Study Group. N Engl J Med 1997; 337: 223-229.
9. Hughes TP, Kaeda J, Branford S, Rudzki Z, Hochhaus A, Hensley ML et al. Frequency of major molecular responses to imatinib or interferon alfa plus cytarabine in newly diagnosed chronic myeloid leukemia. N Engl J Med 2003; 349: 1423-1432.
10. Hochhaus A, Reiter A, Saußele S, Reichert A, Emig M, Kaeda J et al. Molecular heterogeneity in complete cytogenetic responders after interferon-alpha therapy for chronic myelogenous leukemia: low levels of minimal residual disease are associated with continuing remission. German CML Study Group and the UK MRC CML Study Group. Blood 2000; 95: 62-66.
11. Bonifazi F, de Vivo A, Rosti G, Guilhot F, Guilhot J, Trabacchi E et al. Chronic myeloid leukemia and interferon-alpha: A study of complete cytogenetic responders. Blood 2001; 98: 3074-3081.
12. Mahon FX, Delbrel X, Cony-Makhoul P, Fabères C, Boiron JM, Barthe C et al. Follow-up of complete cytogenetic remission in patients with chronic myeloid leukemia after cessation of interferon alfa. J Clin Oncol 2002; 20: 214-220.
13. Cortes J, O'Brien S, Kantarjian H. Discontinuation of imatinib therapy after achieving a molecular response. Blood 2004; 104: 2204-2205.
14. Mauro MJ, Druker BJ, Maziarz RT. Divergent clinical outcome in two CML patients who discontinued imatinib therapy after achieving a molecular remission. Leukemia Res 2004; 28: S71-S73.
15. Rousselot P, Charbonnier A, Cony-Makhoul P, Agape P, Nicolini FE, Varet B et al. Loss of major molecular response as a trigger for restarting tyrosine kinase inhibitor therapy in patients with chronic-phase chronic myelogenous leukemia who have stopped imatinib after durable undetectable disease. J Clin Oncol 2013; 32: 424-430.
16. Mahon F-X, Réa D, Guilhot J, Guilhot F, Huguet F, Nicolini F et al. Discontinuation of imatinib in patients with chronic myeloid leukaemia who have maintained complete molecular remission for at least 2 years: the prospective, multicentre Stop Imatinib (STIM) trial. Lancet Oncol 2010; 11: 1029-1035.
17. Ross DM, Branford S, Seymour JF, Schwarer AP, Arthur C, Yeung DT et al. Safety and efficacy of imatinib cessation for CML patients with stable undetectable minimal residual disease: results from the TWISTER study. Blood 2013; 122: 515-522.
18. Merante S, Orlandi E, Bernasconi P, Calatroni S, Boni M, Lazzarino M. Outcome of four patients with chronic myeloid leukemia after imatinib mesylate discontinuation. Haematologica 2005; 90: 979-981.
19. Rousselot P, Huguet F, Réa D, Legros L, Cayuela JM, Maarek O et al. Imatinib mesylate discontinuation in patients with chronic myelogenous leukemia in complete molecular remission for more than 2 years. Blood 2007; 109: 58-60.
20. Burchert A, Wölfl S, Schmidt M, Brendel C, Denecke B, Cai D et al. Interferon-alpha, but not the ABL-kinase inhibitor imatinib (STI571), induces expression of myeloblastin and a specific T-cell response in chronic myeloid leukemia. Blood 2003; 101: 259-264.
21. Molldrem JJ, Lee PP, Wang C, Felio K, Kantarjian HM, Champlin RE et al. Evidence that specific T lymphocytes may participate in the elimination of chronic myelogenous leukemia. Nat Med 2000; 6: 1018-1023.
22. Molldrem JJ, Lee PP, Kant S, Wieder E, Jiang W, Lu S et al. Chronic myelogenous leukemia shapes host immunity by selective deletion of high-avidity leukemiaspecific T cells. J Clin Invest 2003; 111: 639-647.
23. Kreutzman A, Rohon P, Faber E, Indrak K, Juvonen V, Kairisto V et al. Chronic myeloid leukemia patients in prolonged remission following interferon- monotherapy have distinct cytokine and oligoclonal lymphocyte profile. PLoS ONE 2011; 6: e23022.
24. Baccarani M, Martinelli G, Rosti G, Trabacchi E, Testoni N, Bassi S et al. Imatinib and pegylated human recombinant interferon-alpha2b in early chronic-phase chronic myeloid leukemia. Blood 2004; 104: 4245-4251.
25. Preudhomme C, Guilhot J, Nicolini FE, Guerci-Bresler A, Rigal-Huguet F, Maloisel F et al. Imatinib plus peginterferon alfa-2a in chronic myeloid leukemia. N Engl J Med 2010; 363: 2511-2521.
26. Simonsson B, Gedde-Dahl T, Markevärn B, Remes K, Stentoft J, Almqvist A et al. Combination of pegylated IFN-2b with imatinib increases molecular response rates in patients with low-or intermediate-risk chronic myeloid leukemia. Blood 2011; 118: 3228-3235.
27. Hehlmann R, Lauseker M, Jung-Munkwitz S, Leitner A, Müller MC, Pletsch N et al. Tolerability-adapted imatinib 800 mg/d versus 400 mg/d versus 400 mg/d plus interferon- in newly diagnosed chronic myeloid leukemia. J Clin Oncol 2011; 29: 1634-1642.
28. Burchert A, Müller MC, Kostrewa P, Erben P, Bostel T, Liebler S et al. Sustained molecular response with interferon alfa maintenance after induction therapy with imatinib plus interferon alfa in patients with chronic myeloid leukemia. J Clin Oncol 2010; 28: 1429-1435.
29. Müller MC, Cross NCP, Erben P, Schenk T, Hanfstein B, Ernst T et al. Harmonization of molecular monitoring of CML therapy in Europe. Leukemia 2009; 23: 1957-1963.
30. Hughes T, Deininger M, Hochhaus A, Branford S, Radich J, Kaeda J et al. Monitoring CML patients responding to treatment with tyrosine kinase inhibitors: review and recommendations for harmonizing current methodology for detecting BCR-ABL transcripts and kinase domain mutations and for expressing results. Blood 2006; 108: 28-37.
31. Cross NCP, White HE, Müller MC, Saglio G, Hochhaus A. Standardized definitions of molecular response in chronic myeloid leukemia. Leukemia 2012; 26: 2172-2175.
32. Burchert A. Maintaining low BCR-ABL signaling output to restrict CML progression and enable persistence. Curr Hematol Malig Rep 2014; 9: 9-16.
33. O'Hare T, Zabriskie MS, Eiring AM, Deininger MW. Pushing the limits of targeted therapy in chronic myeloid leukaemia. Nat Rev Cancer 2012; 12: 513-526.
34. Nicolini FE, Etienne G, Dubruille V, Roy L, Huguet F, Legros L et al. Nilotinib and peginterferon alfa-2a for newly diagnosed chronic-phase chronic myeloid leukaemia (NiloPeg): A multicentre, non-randomised, open-label phase 2 study. Lancet Haematol 2015; 2: e37-e46.
35. Faderl S, Talpaz M, Estrov Z, Kantarjian HM. Chronic myelogenous leukemia: biology and therapy. Ann Intern Med 1999; 131: 207-219.